Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase II Randomized Trial of Olaparib (NSC 747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer.
NCT Number:
NCT03598257
Phase:
II
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Breast
Study Objectives:
This phase II trial studies how well radiation therapy with or without olaparib works in treating patients with inflammatory breast cancer. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep cancer cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. It is not yet known whether radiation therapy with or without olaparib may work better in treating patients with inflammatory breast cancer.
Study Documents
(MUSC NetID required for document access)